knowledge -WSS

knowledge

author：entertainment 2025-09-07 14:01:33 - browse：936

Fran van Delft for Galapagos

Seeking to differentiate itself from other makers of CAR-T cancer therapies, Galapagos NV on Wednesday announced it had struck a deal with Blood Centers of America to open up dozens of manufacturing sites for its cell-based medicines around the U.S.

Galapagos said it will rely on the partnership, the financial terms of which were not disclosed, as it moves its CAR-Ts for different cancers into pivotal studies and could also help launch those medicines should they win approval. The Belgian company framed the collaboration as one that could help overcome the limitations that have held back access to existing CAR-T therapies from other companies.

CAR-Ts have proven to be potent treatments for certain cancers, but they are complicated medicines to make. Immune cells have to be removed from a patient, shipped to specialty sites, where they’re engineered with cancer-killing abilities, and then returned to the hospital for infusion back into patients. The process, which can take weeks if not months, has put a crunch on the number of patients companies and hospitals are able to treat.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Complete sequence of Y chromosome published for first time

focus

leisure time

WSS

FDA panel gives mixed vote on blood pressure devices

Appeals court upholds limits to abortion pill

Winners, losers from Medicare’s list of drugs subject to price talks

FDA panel gives mixed vote on blood pressure devices

Medicare explains how it will choose drugs for negotiation

2024 GOP presidential candidates spar over abortion in debate

hotspot

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

How to save PrEP access — and even expand it

Will.i.am, Britney Spears release new single, 'Mind Your Business'

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Hyaluronic acid injections don’t help knee osteoarthritis, study finds

Trump demands the U.S. pay no more for drugs than other countries … again

AstraZeneca bets AAV gene therapy will still deliver the goods

Supreme Court strikes down use of affirmative action

Body of missing toddler recovered in Delaware River days after flood: Police

Medical records are filled with copy

Body of missing toddler recovered in Delaware River days after flood: Police

hotspot

FDA panel gives mixed vote on blood pressure devices

How a symptom of dementia informs our understanding of creativity

Why an extreme heat and wildfire smoke combination can be so dangerous

CDC backtracks, saying fully vaccinated people can go maskless indoors

HIPAA doesn't protect reproductive records from prosecutors

FDA panel gives mixed vote on blood pressure devices

focus

leisure time

hotspot

explore